Integra Lifesciences (IART) Gets a Hold Rating from Cantor Fitzgerald


In a report released today, Craig Bijou from Cantor Fitzgerald maintained a Hold rating on Integra Lifesciences (NASDAQ: IART), with a price target of $59. The company’s shares opened today at $62.25.

Bijou noted:

“We maintain our Neutral rating and 12-month price target of $59 on IART. Although we view IART’s long-range plan as impressive, we believe execution over the next few quarters is critical to restoring investor confidence in the stock. We think it is appropriate to stay on the sidelines at this time, but we might become more positive on the stock if the company were to execute on its integration and salesforce restructuring goals. We think IART is fairly valued at current levels, appropriately balancing the long-term opportunities with the risk of near-term disruption from the Codman acquisition and the changes to the OTT sales channel structure.”

According to TipRanks.com, Bijou is a 4-star analyst with an average return of 18.4% and a 65.9% success rate. Bijou covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Wright Medical Group, and Stryker Corporation.

Currently, the analyst consensus on Integra Lifesciences is a Hold with an average price target of $65.67.

See today’s analyst top recommended stocks >>

Based on Integra Lifesciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $11.38 million. In comparison, last year the company had a net profit of $10.84 million.

Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Orthopedics and Tissue Technologies segments.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts